Matinas Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) filed this Current Report on Form 8-K on August 14, 2024. The filing primarily serves to announce the Company's financial results for the quarter ended June 30, 2024, via a press release furnished as Exhibit 99.1. Additionally, the Company updated its corporate presentation for use at investor conferences, furnished as Exhibit 99.2.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2), which are incorporated by reference but not included in the text of this 8-K summary.
Material Changes
The filing text does not provide specific data regarding material changes in financial performance compared to the prior comparable period. Investors must refer to the attached press release for a detailed comparison of the quarter ended June 30, 2024, against previous periods.
Guidance, Outlook, and Risks
The Company updated its corporate presentation to reflect current outlook and operational status for investor meetings. The filing explicitly states that the information contained in Item 2.02 and Item 7.01, including the press release and corporate presentation, is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference in other filings.
Key Facts for Investor Verification
- Verify the specific revenue, net loss, and cash burn figures in the attached press release (Exhibit 99.1) for the quarter ended June 30, 2024.
- Review the updated corporate presentation (Exhibit 99.2) for the latest clinical trial timelines and commercialization strategies.
- Confirm the Company's current cash position and runway, as these are not explicitly stated in the 8-K text.
- Note that the financial data in this filing is not legally "filed" for liability purposes under Section 18 of the Exchange Act.